QC Laboratory Deviations

The scenario begins during a routine FDA inspection at a biopharmaceutical facility where the inspectors noted discrepancies in analytical data reports produced by laboratory analysts. As the inspection progressed, several…

During routine batch analysis, QC analysts observed unusual results in potency tests for a specific active pharmaceutical ingredient (API). The results were inconsistent with previous batches, indicating a deviation from…

The initial signal of the issue came from the Quality Control (QC) lab during a routine review of chromatographic data. Analysts observed discrepancies between expected integration results and those recorded…

The initial detection of the issue occurred during a routine data integrity audit within the quality control laboratory. Several team members reported discrepancies in the test records associated with batch…

During the FDA inspection, several symptoms signaled a potential sample preparation error:Click to read the full article.

During a routine review of stability test results, QC analysts noted discrepancies in the results of several stability batches. The following indicators were observed:Click to read the full article.

During routine monitoring of stability studies, QA personnel identified discrepancies in the laboratory records pertaining to the timing of test completions. Symptoms included:Click to read the full article.

The initial symptom that sparked the investigation was the detection of OOS results during routine quality control testing for an API (Active Pharmaceutical Ingredient). The results from two separate batches…

In this case study, the initial symptoms of a potential data integrity breach were detected during routine data reviews in the QC laboratory. Several critical indicators prompted immediate concern:Click to…

The first indication of a potential issue came when the QC laboratory began to notice a rising trend in OOS results during dissolution testing of a specific solid oral dosage…

The initial signals of non-compliance generally arise from results that deviate from established acceptance criteria. In this case, routine quality control testing of a pharmaceutical product revealed inconsistent peak integrations…

During routine internal audits, several symptoms emerged that indicated an underlying problem with the validation of a new analytical method. Symptoms observed included:Click to read the full article.